Multiple Myeloma | Specialty

The OncLive Multiple Myeloma condition center page is a comprehensive resource for clinical news and expert insights on multiple myeloma and how to treat patients with monoclonal antibodies, proteasome inhibitors, bispecific T-cell engagers, immunomodulatory agents, CAR T-cell therapy, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in multiple myeloma.

Talquetamab-Based Triplet Elicits Deep Responses in R/R Myeloma

September 27th 2024

Talquetamab plus daratumumab yields improved patient outcomes in patients with relapsed/refractory multiple myeloma.

Talquetamab Plus Teclistamab Demonstrates Durable Responses in Triple Class–Exposed R/R Myeloma

September 27th 2024

Combining talquetamab with teclistamab demonstrated responses even among those with extramedullary disease in the RedirecTT-1 trial.

Daratumumab Regimen Yields Durable MRD-Negativity in Newly Diagnosed Multiple Myeloma

September 26th 2024

Daratumumab-based induction/consolidation and maintenance therapy resulted in durable MRD negativity in patients with newly diagnosed multiple myeloma.

D-VRd Extends PFS in Newly Diagnosed Multiple Myeloma Subgroups

September 26th 2024

D-VRd induction and consolidation therapy displayed a PFS benefit vs VRd in high-risk subgroups of patients with newly diagnosed multiple myeloma.

KarMMa-9 Study of Ide-Cel/Lenalidomide Maintenance in Newly Diagnosed Myeloma Discontinues Enrollment

September 25th 2024

The phase 3 KarMMa-9 trial of ide-cel plus lenalidomide maintenance in newly diagnosed multiple myeloma after ASCT has discontinued enrollment.

Dr Banerjee on Deciding Between CAR T-Cell Therapy and Bispecific Antibodies in Myeloma

September 24th 2024

Rahul Banerjee, MD, FACP, discusses criteria utilized in deciding between treatment with bispecific antibodies and CAR T-cell therapy in multiple myeloma.

FDA Approves Isatuximab Plus VRd for Newly Diagnosed, Transplant-Ineligible Multiple Myeloma

September 20th 2024

The FDA has approved isatuximab plus bortezomib, lenalidomide, and dexamethasone for newly diagnosed, transplant-ineligible myeloma.

Subcutaneous Daratumumab Quadruplet Approaches EU Approval for Newly Diagnosed Myeloma

September 20th 2024

The EMA's CHMP has recommended the approval of subcutaneous daratumumab plus VRd in patients with newly diagnosed, transplant-eligible multiple myeloma.

Clinical Pearls & Unmet Needs in Early and Late Relapse R/R MM

September 18th 2024

The relapsed/refractory multiple myeloma experts conclude by highlighting current unmet needs in the field and sharing valuable clinical pearls to guide practice and improve patient outcomes.

Dr Lonial on the Impact of the CoMMpass Study on Personalized Medicine in Multiple Myeloma

September 18th 2024

Sagar Lonial, MD, FACP, discusses the broad impact of the CoMMpass study on understanding the molecular underpinnings of multiple myeloma.

Approval Sought for Belantamab Mafodotin Combos for R/R Multiple Myeloma in Japan

September 18th 2024

Japan’s Ministry of Health, Labour, and Welfare has accepted the NDA for belantamab mafodotin plus bortezomib/dexamethasone in relapsed/refractory myeloma.

FDA Grants RMAT Designation to P-BCMA-ALL01 for R/R Multiple Myeloma

September 17th 2024

The FDA has granted regenerative medicine advanced therapy designation to P-BCMA-ALL01 for relapsed/refractory multiple myeloma.

Belantamab Mafodotin Plus Vd Earns Breakthrough Therapy Designation in China for R/R Myeloma

September 17th 2024

China’s NMPA granted breakthrough therapy designation to belantamab mafodotin plus bortezomib and dexamethasone in relapsed/refractory myeloma.

Dr Banerjee on the Benefit of Bispecific Antibody Dose Reduction in Multiple Myeloma

September 16th 2024

Rahul Banerjee, MD, FACP, discusses clinical benefits derived when reducing the dosing of bispecific antibodies in the management of multiple myeloma.

Myeloma Molecular Profiling Reveals Unique Copy Number and Expression Subtypes

September 13th 2024

Findings from a molecular analysis of the CoMMpass study identified copy number and expression subtypes of high-risk, newly diagnosed multiple myeloma.

Dr Banerjee on the Impact of Dose Modification Studies in Multiple Myeloma

September 13th 2024

Rahul Banerjee, MD, FACP, discusses the clinical impact of dose modification studies on the treatment of patients with multiple myeloma.

CoMMpass Data Continue to Shape Understanding of Genomic Diversity in Multiple Myeloma

September 12th 2024

Sagar Lonial, MD, FACP, discusses how genetic data from the CoMMpass trial continue to affect the understanding of multiple myeloma.

Potential Novel Lab Monitoring & Key Takeaways for Heavily Pre-Treated R/R MM

September 11th 2024

The key opinion leaders provide essential insights and recommendations for community oncologists to enhance and optimize treatment strategies for their patients with relapsed/refractory multiple myeloma.

Challenges of Treatment Sequencing in Heavily Pre-Treated R/R MM: Expert Insights

September 11th 2024

The experts in relapsed/refractory multiple myeloma care outline their treatment sequencing strategies for patients who have already received T-cell engaging therapies.

Dr Lonial on Characterizing Multiple Myeloma Subtypes in the CoMMpass Study

September 10th 2024

Sagar Lonial, MD, FACP, discusses unique subtypes of multiple myeloma identified through the CoMMpass study.